EUVIMEDEUVIMED entdecken
Crossref

Practical Management of Bispecific Antibodies in Multiple Myeloma

Carlyn Rose Tan iD, Neha Korde iD, Hira Mian iD

JCO Oncology Practice · 17.06.2026

DOI: 10.1200/op-26-00159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 17.06.2026. Verfasst von Carlyn Rose Tan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Die Arbeit nennt 79 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape for relapsed/refractory multiple myeloma has been transformed by the approval of T-cell–redirecting bispecific antibodies (BsAbs) targeting B-cell maturation antigen (teclistamab, elranatamab, and linvoseltamab) and GPRC5D (talquetamab). Although pivotal trials have demonstrated deep and durable responses, the rapid transition of these off-the-shelf agents from controlled clinical settings to routine oncologic practice presents significant operational and clinical challenges. This review focuses on the practical framework required to deliver BsAb therapy safely and effectively across academic and community settings. We address critical components of patient selection and effective implementation strategies, including infrastructure for the management of unique short-term toxicities such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, and long-term infection risks. We discuss models for outpatient implementation of these agents including the use of technology and academic-community partnerships (shared care models). As BsAbs move into earlier lines of therapy and combination regimens, optimizing these practical management strategies is essential to ensuring equitable access and maximizing long-term outcomes for patients with multiple myeloma.

Autor:innen und Institutionen

  • Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Oncology, McMaster University, Hamilton, Canada.

ORCID-Profile: Carlyn Rose Tan, Neha Korde, Hira Mian

Zitieren

APA

Tan, C. R., Korde, N., & Mian, H. (2026). Practical Management of Bispecific Antibodies in Multiple Myeloma. JCO Oncology Practice. https://doi.org/10.1200/op-26-00159

Vancouver

Tan CR, Korde N, Mian H. Practical Management of Bispecific Antibodies in Multiple Myeloma. JCO Oncology Practice. 2026. doi:10.1200/op-26-00159

BibTeX
@article{Tan2026,
  author = {Tan, Carlyn Rose and Korde, Neha and Mian, Hira},
  title = {Practical Management of Bispecific Antibodies in Multiple Myeloma},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-26-00159}
}
Kostenlos starten →